

NASDAQ: MRVI

Craig Hallum Bioprocessing Conference

September 19, 2024



Maravai's Business Segments

Biologics Safety Testing


Critical for process impurity detection and quantification

- Broad applicability across biologic manufacturing
- Driven by growth demand for cell and gene therapy production
- Loyal bioprocessing customer base
- Custom analytical method and assay development programs
- Orthogonal expansion into Mass Spec for bioprocess design
- HCP kits used in 23 out of 23 commercialized CAR-T cell and gene therapies plus the first-ever CAR-T approval in China

Nucleic Acid Production

Highly modified nucleic acids and enzymes for research, therapeutic and vaccine programs

- Specialty in complex nucleic acid synthesis
- Meeting growing customer need for outsourced research-grade to GMP-grade components
- Extensive catalog of nucleic acid building blocks
- New product innovation:
 - CleanCap® M6, most robust cap analog
 - N1-Methyl-Pseudouridine-5'-Triphosphate, critical raw material for mRNA therapeutics
- Alphazyme acquisition adds critical enzyme manufacturing capabilities



MARAVAI SHARED SERVICES (“CORPORATE”)

Science & Innovation | Commercial | Finance & IT | HR, Global Operations, and Business Transformation | Legal

1. Percentage represents share of total revenue for the TTM ended June 30, 2024

2 ©2024 Maravai LifeSciences. This document and its contents are confidential and proprietary and are not to be shared or redistributed without express consent.

Exciting Product Portfolio Supports Customer Needs

CleanCap® Technology



CleanCap® AG

✓ Already in approved vaccine

CleanCap® 3'OMe

✓ Already in approved vaccine



CleanCap® AU

Self-amplifying mRNA

✓ Already in approved vaccine

CleanCap® M6 Potential for 30%+ higher protein production

NTPs



Decades of experience developing and producing modified NTPs



Brings scientific capabilities and innovative chemistry approaches for NTP development and production

Oligonucleotides



Foundational oligonucleotide producer for next-generation sequencing, molecular diagnostics and genomic tools companies



Provides reagents, supports, modifiers and labelling technologies for oligonucleotide synthesis

Enzymes



Provides unique expertise in molecular biology, enzyme scale-up, and production services

Leveraging San Diego Manufacturing Capability



mRNA and related raw material manufacturing

- 118,000 ft² (10,963 m²)
- Discovery and GMP mRNA manufacturing services
- CleanCap® technology and NTP and oligo innovation and scale up
- On-site quality control lab



Analytical and support services

- 54,232 ft² (5,038 m²)
- Home of the Analytical Sciences Center of Excellence (ASCE)



GMP nucleic acid production

- 32,000 ft² (2,973 m²)
- CleanCap® technology and NTP production for clinical and commercial use
- On-site quality control lab
- BARDA Award



cGMP mRNA manufacturing

- 32,000 ft² (2,973 m²)
- Phase 2 clinical through commercial manufacturing
- On-site quality control lab

CleanCap® M6 Most Robust Capping Analog Available



Provides category leading capping efficiency of >95%

- Increased IVT efficacy resulting in high manufacturing yield
- Demonstrates reduced immunogenicity compared to other cap analogs



New cap structure can produce 30%+ higher protein expression




- Increases potency of your mRNA drug substance
- Allows for lower dosing resulting in higher manufacturing yield



Maintains the one-pot workflow benefit of CleanCap

- Simplified manufacturing process, decreasing process risk
- Lowers time, labor, and cost to manufacture

CleanCap[®] M6 makes mRNA more potent – superior protein expression compared to enzymatically capped mRNA



*** p < 0.001, two-tailed T test. Error bars are standard error of mean. n = 9/group

Cygnus Participates Throughout the Drug Development Cycle

